1-8 of 8
Chris Twelves
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

Hope S. Rugo, Javier Cortes, Ahmad Awada, Joyce O'Shaughnessy, Chris Twelves, Seock-Ah Im, Alison Hannah, Lin Lu, Sherwin Sy, Katie Caygill, Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3348–3357.
https://doi.org/10.1158/1078-0432.CCR-17-3059
Published: 15 July 2018
View article titled, Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Open the PDF for Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Sarah Blagden, Aurelius Olmin, Debra Josephs, Chara Stavraka, Andrea Zivi, David J. Pinato, Alan Anthoney, Shaun Decordova, Karen Swales, Ruth Riisnaes, Lorna Pope, Kohei Noguchi, Rie Shiokawa, Michiyasu Inatani, Jenny Prince, Keith Jones, Chris Twelves, James Spicer, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5908–5917.
https://doi.org/10.1158/1078-0432.CCR-14-1315
Published: 30 November 2014
View article titled, First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Open the PDF for First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients

Liane M. McGlynn, Tove Kirkegaard, Joanne Edwards, Sian Tovey, David Cameron, Chris Twelves, John M.S. Bartlett, Timothy G. Cooke
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1487–1495.
https://doi.org/10.1158/1078-0432.CCR-07-4967
Published: 19 February 2009
View article titled, Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients
Open the PDF for Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors

Gernot Beutel, Hilary Glen, Patrick Schöffski, Jon Chick, Stan Gill, James Cassidy, Chris Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5487–5495.
https://doi.org/10.1158/1078-0432.CCR-05-0104
Published: 01 August 2005
View article titled, Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors
Open the PDF for Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors in another window
Journal Articles

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

Ramon Salazar, Donald Bissett, Chris Twelves, Lars Breimer, Mark DeMario, Sophia Campbell, Jay Zhi, Steve Ritland, Jim Cassidy
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4374–4382.
https://doi.org/10.1158/1078-0432.CCR-04-0135
Published: 06 July 2004
View article titled, A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors
Open the PDF for A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors in another window
Journal Articles

Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors

Hans Gelderblom, Ramon Salazar, Jaap Verweij, George Pentheroudakis, Maja J. A. de Jonge, Martin Devlin, Christel van Hooije, Francis Seguy, Rosendo Obach, Joan Pruñonosa, Paola Principe, Chris Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4101–4107.
Published: 30 September 2003
View article titled, Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors
Open the PDF for Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors in another window
Journal Articles

Effect of Hepatic Dysfunction due to Liver Metastases on the Pharmacokinetics of Capecitabine and Its Metabolites

Chris Twelves, Robert Glynne-Jones, Jim Cassidy, Johannes Schüller, Timothy Goggin, Brigitte Roos, Ludger Banken, Masahiro Utoh, Erhard Weidekamm, Bruno Reigner
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1696–1702.
Published: 01 July 1999
View article titled, Effect of Hepatic Dysfunction due to Liver Metastases on the Pharmacokinetics of Capecitabine and Its Metabolites
Open the PDF for Effect of Hepatic Dysfunction due to Liver Metastases on the Pharmacokinetics of Capecitabine and Its Metabolites in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

Paul A. Vasey, Stan B. Kaye, Rosemary Morrison, Chris Twelves, Peter Wilson, Ruth Duncan, Alison H. Thomson, Lilian S. Murray, Tom E. Hilditch, Tom Murray, Sally Burtles, D. Fraier, E. Frigerio, Jim Cassidy, on behalf of the Cancer Research Campaign Phase I/II Committee
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 83–94.
Published: 01 January 1999
View article titled, Phase I Clinical and Pharmacokinetic Study of PK1 [<em>N</em>-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
Open the PDF for Phase I Clinical and Pharmacokinetic Study of PK1 [<em>N</em>-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates in another window